1997

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women With Polycystic Ovary Syndrome

Top

Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women With Polycystic Ovary Syndrome.  J Clin Endocrinol Metab. 1997;82:2108-2116. Women with polycystic ovary syndrome (PCOS)are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects.

Treatment With the Oral Antidiabetic Agent Troglitazone Improves (Beta) Cell Responses to Glucose in Subjects With Impaired Glucose Tolerance

Top

Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment With the Oral Antidiabetic Agent Troglitazone Improves (Beta) Cell Responses to Glucose in Subjects With Impaired Glucose Tolerance  J Clin Invest. 1997;100:530-537. Impaired glucose tolerance (IGT) is associated with defects in both insulin secretion and action and carries a high risk for conversion to non-insulin dependent diabetes mellitus (NIDDM). Troglitazone, an insulin sensitizing agent, reduces glucose concentrations in subjects with NIDDM and IGT but is not known to affect insulin secretion.

TNF-a-Induced Insulin Resistance In Vivo and Its Prevention by Troglitazone

Top

Miles PDG, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM. Diabetes TNF-a-Induced Insulin Resistance In Vivo and Its Prevention by Troglitazone Diabetes. 1997;46:1678-1683. Tumor necrosis factor (TNF)-a may play a role in the insulin resistance of obesity and NIDDM. Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and NIDDM subjects.

Model of Complications of NIDDM - II. Analysis of the Health Benefits and Cost-effectiveness of Treating NIDDM With the Goal of Normoglycemia

Top

Eastman RC, Javitt JC, Herman WH, et al. Diabetes Care Model of Complications of NIDDM II. Analysis of the Health Benefits and Cost-effectiveness of Treating NIDDM With the Goal of Normoglycemia. Diabetes Care. 1997;20:735-744. To analyze the health benefits and economics of treating NIDDM with the goal of normoglycemia.

Model of Complications of NIDDM - I. Model Construction and Assumptions

Top

Eastman RC, Javitt JC, Herman WH, et al. Diabetes Care Model of Complications of NIDDM - I. Model Construction and Assumptions. Diabetes Care. 1997;20:725-734. To develop a model of NIDDM for analyzing prevention strategies for NIDDM.

Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes

Top

Vijan S, Hofer TP, Hayward RA. Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes. Ann Intern Med. 1997;127:788-795. The benefits of intensive glycemic control in patients with type 2 diabetes are not well quantified. It is therefore not clear which patients will benefit most from aggressive glycemic control.

Coronary Heart Disease Events in Middle-Aged Patients With NIDDM

Top

Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Diabetes Coronary Heart Disease Events in Middle-Aged Patients With NIDDM. Diabetes. 1997;46:1354-1359. Patients with NIDDM are at increased risk for coronary heart disease (CHD). However, information on the predictive value of cardiovascular risk factors and the degree of hyperglycemia with respect to the risk for CHD in diabetic patients is still limited.